UPDATE : 6 December 2025 - 16:54
13.8 C
Napoli
UPDATE : 6 December 2025 - 16:54
13.8 C
Napoli

Significant findings in chronic inflammatory bowel disease with guselkumab

Listen to this article now...
Loading ...
Significant findings in chronic inflammatory bowel disease with guselkumab

Guselkumab, a fully human monoclonal antibody, is confirmed as a promising therapeutic solution for inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. During the recent Congress of the Italian Group of Inflammatory Bowel Disease, Johnson & Johnson revealed significant results regarding the efficacy and safety of the treatment.

Search Details

This drug selectively targets the p19 subunit of interleukin-23 (IL-23), highlighting its potential to treat complex conditions involving the immune system. The presentations provided further confirmation of guselkumab's crucial role in the management of these inflammatory disorders.

Therapeutic Impact

The continued exploration of the properties of guselkumab could represent a step forward in the treatment options available for patients affected by these chronic diseases. The data that have emerged underline the possibility of significantly improving the quality of life through targeted and well-tolerated therapies.

Article published on November 29, 2024 - 19:18 PM - Matteo Setaro

Daily News

Top News

PODCAST
Latest episodes
Chip-controlled "biodrones" pigeons: first tests in Russia, but independent verification is lacking
Chip-controlled "biodrones" pigeons: first tests in Russia, but independent verification is lacking
👉 Read the article
0:00 0:00
Theft
Ad is loading…